NPR reports, “A special Food and Drug Administration process to get patients earlier access to new drugs has come under fire. The accelerated approval process speeds medicines to market based on preliminary study data.” However, “there’s a condition: The drugmaker needs to do an additional study after the drug is on the market to prove the drug really works. If the study doesn’t pan out, the drug can be pulled off the market.” Some drugmakers, however, “have fallen behind on their commitments to do those confirmatory studies, leaving patients and their doctors to make difficult decisions with incomplete information.” The publication “examined 30 years of government data and records and conducted dozens of interviews as part of its investigation,” coming up with five key details.
From the news release of the American Association for Justice.

